The Danish Biotech Company Meta-IQ announces that it has engaged Back Bay Life Science Advisors, a Boston-based, international strategic consulting and advisory firm, to help in the further development and definition of Meta-IQ’s value proposition and development planning.
Since inception in 2010, Back Bay has completed over 170 strategic projects for North American and European clients. Many of these assignments have involved primary corporate development support for large and midcap Biotech and Pharma assessing opportunities in the inflammation and neurologic fields including treatments for acute ocular neuritis (AON) and secondary progressive multiple sclerosis (SP-MS). In addition, Back Bay’s transactional division has led the successful exit of 5 biotech companies and maintains a robust pipeline of activity in acquisition, licensing and partnering for both sell and buy side clients.
Ingelise Saunders, CEO of Meta-IQ comments: “We are very pleased that we have been able to get Back Bay on board to work alongside management at this very exciting and important time for the company. We have started to work on the development plans for the two chosen indications and need to define the value proposition for the company to be able to kick off the fundraising process shortly. We look very much forward to working together with the Back Bay team again and to take the project into the patients in AON and SP-MS where there is a huge unmet medical need.”
Jonathan P Gertler MD, CEO and Managing Partner of Back Bay Life Science Advisors comments, “We are delighted to be working with Meta-IQ as the company potentially will offer a novel effective solution to patients with AON and SP-MS. The Back Bay and Meta-IQ teams have worked together previously with great success on the strategic planning and ultimate sale of Action Pharma to Abbott. We are extremely pleased to be together again and are committed to helping the company define a productive and rewarding path forward for its shareholders, management, and the provider/patient community that its technology will serve.”
About Meta-IQ
Meta-IQ is a Danish biotech company that develops innovative treatment for Acute ocular neuritis (AON) and Secondary progressive multiple sclerosis (SP-MS) by inhibiting CPT1 (the key molecule in fat metabolism) and thus resetting the energy metabolism from fatty-acid back to glucose resulting in neuro-protective and anti-inflammatory properties. Meta-IQ has reached proof of concept in animal models for the small molecule compound MIQ-001. MIQ-001 is working via a new mode of action and has shown exceptional efficacy in these diseases, with findings independently confirmed by leading international researchers. www.Meta-IQ.com
For additional comments please contact:
Ingelise Saunders
CEO
Meta-IQ
ingelise.saunders@meta-iq.com
Phone: +45 20203687
Jarne Elleholm
Chairman of the Board of Directors
Meta-IQ
jarne.elleholm@meta-iq.com
Phone: +45 41190136
Jonathan P. Gertler MD
CEO and Managing Partner
Back Bay Life Science Advisors
jgertler@bblsa.com
Phone: +1 617-933-5814
